BIOGEN INC. Other Comprehensive Income (Loss), Available-for-sale Securities, Tax (Deprecated 2012-01-31)
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Available-for-sale Securities, Tax (Deprecated 2012-01-31) of $1.12 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-01.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeAvailableForSaleSecuritiesTax · last filed 2012-05-01
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $1.12M, a 83.80% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $188.00K.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $800.00K, a 76.47% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $600.00K, a 84.21% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for fiscal 2011 was $7.29M, a 957.76% increase from fiscal 2010.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for fiscal 2010 was $689.00K, a 81.32% increase from fiscal 2009.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for fiscal 2009 was $380.00K, a 66.16% decline from fiscal 2008.
- BIOGEN INC. other comprehensive income (loss), available-for-sale securities, tax (deprecated 2012-01-31) for fiscal 2008 was $1.12M.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $1.12M 10-Q · filed 2012-05-01 | $1.31M derived: sum of 2 quarters · filed 2012-05-01 | $2.11M derived: sum of 3 quarters · filed 2012-05-01 | $2.71M derived: sum of 4 quarters · filed 2012-05-01 |
| 2011-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $988.00K derived: sum of 2 quarters · filed 2012-02-03 | $1.59M derived: sum of 3 quarters · filed 2012-02-03 | $7.29M 10-K · filed 2012-02-03 |
| 2011-09-30 | $800.00K 10-Q · filed 2011-10-28 | $1.40M derived: sum of 2 quarters · filed 2011-10-28 | $7.10M 10-Q · filed 2011-10-28 | $6.92M derived: sum of 4 quarters · filed 2012-05-01 |
| 2011-06-30 | $600.00K 10-Q · filed 2011-07-26 | $6.30M 10-Q · filed 2011-07-26 | $6.12M derived: sum of 3 quarters · filed 2012-05-01 | $9.52M derived: sum of 4 quarters · filed 2012-05-01 |
| 2011-03-31 | $6.93M 10-Q · filed 2012-05-01 | $5.52M derived: sum of 2 quarters · filed 2012-05-01 | $8.92M derived: sum of 3 quarters · filed 2012-05-01 | $12.72M derived: sum of 4 quarters · filed 2012-05-01 |
| 2010-12-31 | -$1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $1.99M derived: sum of 2 quarters · filed 2012-02-03 | $5.79M derived: sum of 3 quarters · filed 2012-02-03 | $689.00K 10-K · filed 2012-02-03 |
| 2010-09-30 | $3.40M 10-Q · filed 2011-10-28 | $7.20M derived: sum of 2 quarters · filed 2011-10-28 | $2.10M 10-Q · filed 2011-10-28 | |
| 2010-06-30 | $3.80M 10-Q · filed 2011-07-26 | $5.50M 10-Q · filed 2011-07-26 | ||
| 2009-12-31 | $380.00K 10-K · filed 2012-02-03 | |||
| 2008-12-31 | $1.12M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |